Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2024-015
    NCT ID
    • NCT06550895
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase II
    Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
    • Phase II
    Principal Investigator
    • Image of Abhinav Deol , M.D.
      Abhinav
      Deol, M.D.
      Oncology - Hematology, Oncology - Medical View Profile

    Objective:

    Primary Objectives:

    • To characterize the safety of cilta-cel and talquetamab

    Secondary Objectives

    • To evaluate the efficacy of cilta-cel and talquetamab
    • To characterize MRD-negativity
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 1-800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 1-800-527-6266